RxDoctor Payments Data

Emily Link

Nurse Practitioner · Wilmington, DENPI 1881038578

Payments from drug & device makers

$1,328in general payments, 2019–2025

Across 35 payments — averaging $37.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AOP Health US, LLC$323
  • Medtronic$265
  • Boehringer Ingelheim$171
  • Heartflow, Inc.$144
  • Pfizer$118
  • Bayer$74
  • plus $233 from 11 others

What the payments were for

  • Food & beverage$1,18889%
  • Education$14011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,328 in reported general payments places this provider in the 80th percentile of 487 nurse practitioner providers in Delaware.

See all nurse practitioner providers in Delaware

Medicare billing

Part B allowed, 2024
$59,937
Medicare patients
451
Services billed
1,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$78,323
JardianceEmpagliflozin36$48,056
EntrestoSacubitril/Valsartan34$46,090
XareltoRivaroxaban13$16,597
Repatha SureclickEvolocumab22$13,104
Metoprolol Succinate164$2,356
Rosuvastatin Calcium73$2,047
Ezetimibe40$1,709
Atorvastatin Calcium106$1,431
Ranolazine ErRanolazine14$1,195
Potassium Chloride19$734
Nebivolol Hcl11$729
Losartan Potassium42$539
Valsartan18$491
Carvedilol43$431

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$118$78,32360 claims
Boehringer IngelheimJardiance$171$48,05636 claims
NovartisEntresto$20$46,09034 claims
Johnson & JohnsonXarelto$12$16,59713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 487 nurse practitioner providers in Delaware.

Other nurse practitioner in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →